VEGFA and macular retinal edema: Currently the most common therapy seeks to inhibit VEGF-A (vascular endothelial cell growth factor-A), a growth factor that promotes increased vascular permeability, macular edema, and neovascularization (Salam et al., 2011; Al-Latayfeh et al., 2012; Bandello et al., 2012; Tremolada et al., 2012; Gupta et al., 2013).